insulin lispro protamine suspension:insulin lispro rDNA origin low mix + insulin glargine
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Type 2 Diabetes
Conditions
Type 2 Diabetes
Trial Timeline
Aug 1, 2003 โ Jul 1, 2005
NCT ID
NCT00191178About insulin lispro protamine suspension:insulin lispro rDNA origin low mix + insulin glargine
insulin lispro protamine suspension:insulin lispro rDNA origin low mix + insulin glargine is a approved stage product being developed by Eli Lilly for Type 2 Diabetes. The current trial status is completed. This product is registered under clinical trial identifier NCT00191178. Target conditions include Type 2 Diabetes.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00191178 | Approved | Completed |
Competing Products
20 competing products in Type 2 Diabetes